Clinical trials: Aggressive Non-Hodgkin Lymphoma
Non-Hodgkin's Lymphoma
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good…
- Trial name
- NCT00250861
- Testing
- Rituximab, Aldesleukin
- Where
- 21 sites in United States
- Volunteers
- 110 people
- Sponsor
- US Oncology Research
Lymphoma, B-Cell
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based…
- Trial name
- NCT04882163
- Testing
- CC-220, Polatuzumab vedotin, Rituximab
- Where
- 27 sites in United States, Austria and 6 more
- Sponsor
- Celgene
Lymphoma, Non-Hodgkin's
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
- Trial name
- NCT00413036
- Testing
- lenalidomide
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 217 people
- Sponsor
- Celgene
Lymphoma
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients…
- Trial name
- NCT00052442
- Testing
- pralatrexate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Relapsed/Refractory Aggressive B-Cell Lymphoma
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810).
- Trial name
- CLIO-1 (NCT02651662)
- Testing
- cemiplimab, odronextamab
- Where
- 30 sites in United States, Austria and 4 more
- Volunteers
- 105 people
- Sponsor
- Regeneron Pharmaceuticals
B-cell Non-Hodgkins Lymphoma (B-NHL)
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug[s]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs).
- Trial name
- ATHENA-1 (NCT05685173)
- Testing
- Odronextamab, REGN5837
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 107 people
- Sponsor
- Regeneron Pharmaceuticals
Hematologic Malignancy
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM)…
- Trial name
- SANGUINE (NCT05735704)
- Testing
- Blood sampling for HemaChip screening/diagnostic testing
- Where
- 4 sites in Czechia, Greece and 2 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
Diffuse Large B-Cell Lymphoma, B-cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0920 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07887646
- Testing
- BG-T0920
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Lymphoma, Extranodal NK-T-Cell, EBV
Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma
- Trial name
- CITADEL (NCT01948180)
- Testing
- baltaleucel-T
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 15 people
- Sponsor
- Cell Medica Ltd
Diffuse Large B-Cell Lymphoma (DLBCL)
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten…
- Trial name
- NCT07887750
- Testing
- REGN9220, Odronextamab
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Tumors, Non Hodgkin's Lymphoma
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.
- Trial name
- NCT00323934
- Testing
- MGCD0103
- Where
- 3 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Mirati Therapeutics Inc.
NHL, DLBCL
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- NHL, DLBCL, Non-hodgkin's Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- PRISM (NCT03527147)
- Testing
- AZD9150, Acalabrutinib, AZD6738
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Acerta Pharma BV
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT00794638
- Testing
- SyB L-0501, Rituximab
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- SymBio Pharmaceuticals
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or…
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Trial name
- NCT05475925
- Testing
- DR-01
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Dren Bio
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Peripheral T-cell Lymphomas
Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
The aim of this study is to evaluate anti-tumor safety and efficacy of endostar®（Human recombinant endostatin injection）combined with traditional GDP （gemcitabine+dexamethasone+cis-platinum）chemotherapy for newly diagnosed or…
- Trial name
- NCT02520219
- Testing
- GDP, Endostar
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing NingQi Medicine Science and Technology Co., Ltd.
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture